...
phar-img

Pharming Group NV, Common Stock

PHAR

NMQ

$9.1

+$0.16

(1.79%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$607.38M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.81K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.81
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.65 L
$13.2 H
$9.1

About Pharming Group NV, Common Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePHARSectorS&P500
1-Week Return1.31%-2.12%-3%
1-Month Return18.49%-3.42%-0.73%
3-Month Return19.97%-11.13%2.87%
6-Month Return11.52%-5.74%7.17%
1-Year Return-18.79%3.97%25.31%
3-Year Return7.95%1.05%28.38%
5-Year Return-45.51%34.37%81.89%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue189.33M228.39M189.85M205.62M245.32M[{"date":"2019-12-31","value":77.18,"profit":true},{"date":"2020-12-31","value":93.1,"profit":true},{"date":"2021-12-31","value":77.39,"profit":true},{"date":"2022-12-31","value":83.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue23.92M25.34M20.18M17.56M25.21M[{"date":"2019-12-31","value":94.41,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.65,"profit":true},{"date":"2022-12-31","value":69.31,"profit":true},{"date":"2023-12-31","value":99.5,"profit":true}]
Gross Profit165.41M203.06M169.67M188.06M220.10M[{"date":"2019-12-31","value":75.15,"profit":true},{"date":"2020-12-31","value":92.25,"profit":true},{"date":"2021-12-31","value":77.09,"profit":true},{"date":"2022-12-31","value":85.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin87.37%88.91%89.37%91.46%89.72%[{"date":"2019-12-31","value":95.52,"profit":true},{"date":"2020-12-31","value":97.21,"profit":true},{"date":"2021-12-31","value":97.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.1,"profit":true}]
Operating Expenses97.19M120.97M156.72M169.83M225.49M[{"date":"2019-12-31","value":43.1,"profit":true},{"date":"2020-12-31","value":53.65,"profit":true},{"date":"2021-12-31","value":69.5,"profit":true},{"date":"2022-12-31","value":75.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income68.23M82.09M27.84M18.23M(4.88M)[{"date":"2019-12-31","value":83.12,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":33.91,"profit":true},{"date":"2022-12-31","value":22.21,"profit":true},{"date":"2023-12-31","value":-5.94,"profit":false}]
Total Non-Operating Income/Expense(26.84M)(22.97M)2.58M(4.22M)(9.57M)[{"date":"2019-12-31","value":-1039.67,"profit":false},{"date":"2020-12-31","value":-889.64,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-163.6,"profit":false},{"date":"2023-12-31","value":-370.55,"profit":false}]
Pre-Tax Income52.29M47.47M22.03M14.99M(12.01M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":90.78,"profit":true},{"date":"2021-12-31","value":42.14,"profit":true},{"date":"2022-12-31","value":28.66,"profit":true},{"date":"2023-12-31","value":-22.97,"profit":false}]
Income Taxes11.74M6.83M6.76M1.31M(1.46M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":58.19,"profit":true},{"date":"2021-12-31","value":57.57,"profit":true},{"date":"2022-12-31","value":11.18,"profit":true},{"date":"2023-12-31","value":-12.47,"profit":false}]
Income After Taxes40.54M40.63M15.27M13.67M(10.55M)[{"date":"2019-12-31","value":99.79,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.59,"profit":true},{"date":"2022-12-31","value":33.65,"profit":true},{"date":"2023-12-31","value":-25.96,"profit":false}]
Income From Continuous Operations36.20M33.03M13.49M13.67M(10.55M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.27,"profit":true},{"date":"2021-12-31","value":37.26,"profit":true},{"date":"2022-12-31","value":37.78,"profit":true},{"date":"2023-12-31","value":-29.14,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income40.54M37.75M16.00M13.67M(10.55M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.1,"profit":true},{"date":"2021-12-31","value":39.45,"profit":true},{"date":"2022-12-31","value":33.73,"profit":true},{"date":"2023-12-31","value":-26.02,"profit":false}]
EPS (Diluted)0.060.160.220.46(0.20)[{"date":"2019-12-31","value":13.28,"profit":true},{"date":"2020-12-31","value":33.74,"profit":true},{"date":"2021-12-31","value":48.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-42.52,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PHAR
Cash Ratio 2.15
Current Ratio 3.53
Quick Ratio 2.76

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PHAR
ROA (LTM) -1.38%
ROE (LTM) -8.18%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PHAR
Debt Ratio Lower is generally better. Negative is bad. 0.47
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.53

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PHAR
Trailing PE NM
Forward PE 169.49
P/S (TTM) 2.16
P/B 2.73
Price/FCF 66
EV/R 1.98
EV/Ebitda 74.74

FAQs

What is Pharming Group NV share price today?

Pharming Group NV (PHAR) share price today is $9.1

Can Indians buy Pharming Group NV shares?

Yes, Indians can buy shares of Pharming Group NV (PHAR) on Vested. To buy Pharming Group NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHAR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pharming Group NV be purchased?

Yes, you can purchase fractional shares of Pharming Group NV (PHAR) via the Vested app. You can start investing in Pharming Group NV (PHAR) with a minimum investment of $1.

How to invest in Pharming Group NV shares from India?

You can invest in shares of Pharming Group NV (PHAR) via Vested in three simple steps:

  • Click on Sign Up or Invest in PHAR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pharming Group NV shares
What is Pharming Group NV 52-week high and low stock price?

The 52-week high price of Pharming Group NV (PHAR) is $13.2. The 52-week low price of Pharming Group NV (PHAR) is $6.65.

What is Pharming Group NV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Pharming Group NV (PHAR) is

What is Pharming Group NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pharming Group NV (PHAR) is 2.73

What is Pharming Group NV dividend yield?

The dividend yield of Pharming Group NV (PHAR) is 0.00%

What is the Market Cap of Pharming Group NV?

The market capitalization of Pharming Group NV (PHAR) is $607.38M

What is Pharming Group NV’s stock symbol?

The stock symbol (or ticker) of Pharming Group NV is PHAR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top